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Abstract Urinary tract infections (UTIs) are some of the most
common infections in both community and hospital settings
infections. With their high rate of incidence, recurrence, com-
plications, diverse etiologic agents, as well as growing antibi-
otic resistance, UTIs have proven to be a serious challenge for
medical professionals. The aim of this study was to obtain data
on the susceptibility patterns of pathogens responsible for
UTIs in Poland to currently used antibiotics. A total of 396
bacterial isolates were collected between March and
May 2013 from 41 centers in all regions of Poland. The ma-
jority of isolates were from adult patients (96.2 %); 144
(37.8 %) patients were diagnosed with uncomplicated UTI,
while the remaining 237 (62.2 %) had a complicated infection.
The most prevalent pathogen was Escherichia coli (71.4 %),
followed by Klebsiella spp. (10.8 %) and the Proteae group
(7.6 %). Escherichia coli was responsible for 80.6 % of cases
of uncomplicated and 65.8 % of complicated infections. Only
65.8 % of E. coli isolates were susceptible to ciprofloxacin
(uncomplicated 75.9 %, complicated 58.3 %), 64.0 % to
nitrofurantoin (67.2 %, 62.8 %), 65.1 % to trimethoprim/
sulfamethoxazole (68.1 %, 62.8%), and 66.4% to fosfomycin
(77.6 %, 62.2 %). Among E. coli isolates from all UTIs, only
43.4 % were susceptible to ampicillin, with 47.4 % from un-
complicated compared with 40.4 % from complicated infec-
tions; 88.2 % to amoxicillin/clavulanic acid (91.4 % vs.
85.9 % complicated); 90.1 % to cefuroxime (93.1 %,
87.8 %); and 94.1 % to cefotaxime (98.2 %, 91.0 %).
Thirty-five strains (10.4 %) were capable of producing
extended-spectrum β-lactamases (ESBLs). This study dem-
onstrates an increase in multidrug-resistant strains, especially
among the leading pathogens associated with UTIs, including
E. coli, Klebsiella spp., and Proteus spp.
Introduction
Urinary tract infections (UTIs) are some of the most common
infections in both community and hospital settings. With their
high rate of incidence, recurrence, complications, diverse eti-
ologic agents, as well as growing antibiotic resistance, UTIs
have proven to be a serious challenge for medical profes-
sionals. They account for 10–20 % of all infections treated
in primary care and 30–40% of infections treated in hospitals.
Rapidly increasing bacterial resistance to antibiotics
resulting in significantly limited treatment options and multi-
drug resistance is a growing concern. Therefore, knowledge of
the current antibiotic susceptibility patterns of the major bac-
terial pathogens responsible for UTIs is important in order to
permit the optimal choice for empiric treatment. The aim of
this study is to provide the most up-to-date data on the epide-
miology, etiology, and susceptibility patterns of major patho-
gens responsible for community-acquired UTIs in Poland. In
addition, clinically important mechanisms of resistance and
risk factors in patients predisposing to UTIs were analyzed.
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Materials and methods
The study was performed in the Department of Epidemiology
and Clinical Microbiology (DECM) of the National
Medicines Institute in Warsaw on a total of 396 bacterial iso-
lates collected betweenMarch andMay 2013 from 41 centers,
representing all regions of Poland. The isolates were recov-
ered from ambulatory patients with clinical symptoms of UTI
and significant bacteriuria [1, 2]. One isolate per patient was
included in the study. The patients’ demographic and epide-
miological data were collected and analyzed.
Identification
All strains were reidentified by using ID GP and ID GN cards
in VITEK Compact (bioMérieux, Marcy l’Etoile, France) and
stored at −70 °C in TSB broth supplemented (with blood for
streptococci) and 10 % glycerol. Before performing further
studies, the strains were unfrozen and subcultured twice on
Columbia agar plates with 5 % sheep blood (Bio-Rad,
Marnes-la-Coquette, France).
Antimicrobial susceptibility
Susceptibility to a range of antibiotics was evaluated by the
disk diffusion method on Mueller–Hinton agar (MHA; Bio-
Rad, Marnes-la-Coquette, France) for Gram-negative rods,
staphylococci, and enterococci, and MHA supplemented with
5 % defibrinated horse blood and 20 mg/L NAD (Bio-Rad,
Marnes-la-Coquette, France) for streptococci. Reading of the
disk diffusion susceptibility results was performed automati-
cally using the ADAGIO apparatus (Bio-Rad, Marnes-la-
Coquette, France).
The following disks for susceptibility testing were used:
ampicillin (10 μg), amoxicillin/clavulanic acid (20 μg/
10 μg), amikacin (30 μg), benzylpenicillin (1 U), cefalexin
(30 μg), cefepime (30 μg), cefotaxime (30 μg), ceftazidime
(30 μg), cefuroxime (30 μg), ciprofloxacin (5 μg), erythromy-
cin (15 μg), gentamicin (10 μg), gentamicin (30 μg),
imipenem (10 μg), clindamycin (2 μg), meropenem (10 μg),
nitrofurantoin (100 μg), piperacillin/tazobactam (100 μg/
10 μg), teicoplanin (30 μg), trimethoprim/sulfamethoxazole
(11.25 μg/23.75 μg), fosfomycin (200 μg), vancomycin
(5 μg) (Bio-Rad, Marnes-la-Coquette, France). Minimum in-
hibitory concentrations (MICs) were determined by VITEK
Compact (bioMérieux, Marcy l’Etoile, France) and, in addi-
tion, by antibiotic gradient strips, Etest (bioMérieux, Marcy
l’Etoile, France), and MICE (Oxoid Limited, Hampshire,
United Kingdom), for extended-spectrum β-lactamase
(ESBL)-producing strains.
The interpretation of susceptibility results was performed
according to the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) guidelines [3], with the
exception of fosfomycin, which was interpreted according to
the Clinical and Laboratory Standards Institute (CLSI) guide-
lines [4].
ESBL production was detected by the double-disk synergy
test (DDST) [5]. To detect genes encoding ESBLs, specific
primers were used for polymerase chain reaction (PCR) as-
says. β-Lactamases were profiled by isoelectrofocusing, as
described previously [6–8]. Total bacterial DNAwas purified
with a Genomic DNA Prep Plus kit (A&A Biotechnology,
Gdansk, Poland). PCR products were subjected to electropho-
resis in a 1 % agarose gel (Blirt, Gdansk, Poland) with
ethidium bromide (Merck, Darmstadt, Germany).
High-level aminoglycoside resistance (HLAR) detection in
enterococci was performed by disk diffusion with a 30-μg
gentamicin disk (Bio-Rad, Marnes-la-Coquette, France) [3].
Quality control
Escherichia coli ATCC 25922, E. coli ATCC 35218,
Enterococcus faecalis ATCC 29212, Klebsiella pneumoniae
ATCC 700603, Pseudomonas aeruginosa ATCC 27853, and
Streptococcus pneumoniae ATCC 49619 from the collection
of the National Medicines Institute in Warsaw were used as
reference strains.
Results
The majority of isolates were from adult patients (n=381;
96.2 %) aged 19 to 94 years (average 60 years), with patients
aged less than 40 years (n=67) accounting for 17.6 % of the
total. As there were only 15 isolates (3.8 %) from children
aged 1–18 years, these were excluded from further analysis.
Among isolates from adults, more than 77.2 % (n=294) were
derived from females, and females predominated in all age
groups. The majority of strains (n=207; 54.3 %) were derived
from patients aged 65 years and over, of which 150 (72.5 %)
were from females and 57 (27.5 %) were from males. One
hundred and forty-four (37.8 %) patients were diagnosed with
uncomplicated UTI, while the remaining 237 (62.2 %) had a
complicated infection. The latter group comprised patients
presenting with recurrent UTI (n= 126; 58.3 %), urinary/
fecal incontinence (n = 67; 31.0 %), nephritis (n = 51;
23.6 %), kidney stones (n=46, 21.3 %), prostate hypertrophy
(n=12; 5.56 %), renal insufficiency (n=7; 3.2 %), diabetes
(n=9; 4.17 %), kidney empyema (n=4; 1.85 %), polycystic
kidneys (n=3; 1.39 %), and kidney cancer (n=3; 1.39 %).
Aerobic Gram-negative bacteria were the dominant patho-
gens (n=356; 93.4 %). The majority (n=347; 91.1 %) of
isolates belonged to the Enterobacteriaceae, while 9 (2.5 %)
strains belonged to the non-fermenting rods. The most fre-
quently isolated species from both uncomplicated and compli-
cated infections were E. coli (71.4 %), followed by Klebsiella
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spp. (10.8 %) and the Proteae group (7.6 %), including
Proteus mirabilis, P. vulgaris, Providencia rettgeri, and
Morganella morganii in uncomplicated UTI. Escherichia coli
was responsible for 80.6 % of cases, compared with 65.8 % of
complicated cases. The proportion of Klebsiella spp. and
Proteus spp. causing complicated UTIs was higher compared
with those causing uncomplicated infections, accounting for
13.5 % vs. 6.3 % and 9.7 % vs. 3.5 %, respectively.
Escherichia coli was mainly responsible for UTIs in females
(n=229; 77.9 %), followed by Klebsiella spp. (n=26; 8.8 %)
and Proteus spp. (n=13; 4.4 %). In females aged less than
65 years, E. coli accounted for 86.7 % of uncomplicated and
74.7 % of complicated infections (p=0.34). Among females
aged 65 years and over, E. coli was responsible for 72.1 % of
uncomplicated and 68.5 % of complicated infections. It is
interesting that, among females aged less than 30 years
(n=36), E. coli and E. faecalis were responsible for 88.9 %
and 11.1 % of UTIs, respectively, with no other pathogen
isolated.
Almost half of the isolates from UTI in men were E. coli
(n=43; 49.4 %), followed by Klebsiella spp. (n=15; 17.2 %).
A higher proportion of Proteus spp. was observed in men
compared to women, with 16.1 % and 4.4 %, respectively
(p=0.01).
Susceptibility to antimicrobial agents was higher
among isolates from uncomplicated than complicated in-
fections (Table 1). Among E. coli isolates from all UTIs,
only 43.4 % were susceptible to ampicillin, with 47.4 %
from uncomplicated compared with 40.4 % from compli-
cated infections; 88.2 % to amoxicillin/clavulanic acid
(91.4 % uncomplicated, 85.9 % complicated); 90.1 %
to cefuroxime (93.1 %, 87.8 %); and 94.1 % to cefotax-
ime (98.2 %, 91.0 %). Only 65.8 % of E. coli isolates
were susceptible to ciprofloxacin (uncomplicated
75.9 %, complicated 58.3 %), 64.0 % to nitrofurantoin
( 6 7 . 2 % , 62 . 8 % ) , 6 5 . 1 % t o t r im e t h op r im /
sulfamethoxazole (68.1 %, 62.8 %), and 66.4 % to
fosfomycin (77.6 %, 62.2 %). Resistance to three or
more drugs was higher among isolates recovered from
complicated than uncomplicated infections (41.0 % vs.
13.8 %). The most common resistance phenotype com-
prised resistance to ampicillin, ciprofloxacin, and tri-
methoprim/sulfamethoxazole. Over 90 % of E. coli iso-
lates recovered from both types of infections were sus-
ceptible to aminoglycosides, third- and fourth-generation
cephalosporins, and piperacillin/tazobactam, and all were
susceptible to carbapenems.
In women aged 65 years or more with uncomplicated in-
fections, susceptibility of E. coli to ciprofloxacin and
trimethoprim/sulfamethoxazole was lower than in those aged
less than 65 years (88.9 % vs. 54.6 % and 76.4 % vs. 54.6 %,
respectively). In addition, differences were observed in the
susceptibility of E. coli to trimethoprim/sulfamethoxazole
and ciprofloxacin recovered from complicated infections in
men versus women (68.1 % vs. 48.8 % and 62.8 % vs.
46.5 %, respectively).
Product ion of ESBLs was found in 2 .8 % of
Enterobacteriaceae recovered from uncomplicated infections
compared with 13.5 % of isolates from complicated infec-
tions.Klebsiella pneumoniaewas the pathogenmost frequent-
ly associated with ESBL production, with 46.2 % of all
K. pneumoniae isolates being positive.
All ESBLs belonged to the CTX-M family and were clas-
sified on the basis of their reaction with specific primers, with
35 isolates belonging to CTX-M-1 and one to CTX-M-9.
Only nine non-fermenting Gram-negative rods were iden-
tified: seven Pseudomonas aeruginosa and two Acinetobacter
baumannii. These were all recovered from patients with com-
plicated UTI. Pseudomonas aeruginosa isolates were broadly
susceptible to the key antibiotics tested, with 100 % suscepti-
bility to carbapenems, ciprofloxacin, piperacillin/tazobactam,
and gentamicin. One of the A. baumannii strains was resistant
to carbapenems.
Gram-positive cocci were isolated from 25 patients and
accounted for 6.6 % of all the isolates, with 20 E. faecalis
and five S. agalactiae identified. The former were most fre-
quently recovered from females (n=13), while S. agalactiae
were isolated exclusively from females. In 48% of cases, both
of these pathogens were responsible for complicated infec-
tions. The E. faecalis isolates were fully susceptible to peni-
cillin, ampicillin, nitrofurantoin, fosfomycin, and vancomy-
cin; however, almost 35 % presented with the HLAR pheno-
type. Streptococcus agalactiae was fully susceptible to the
antibiotics tested.
Discussion
The data presented show that E. coli remains the most
common etiologic agent of community-acquired UTI in
Poland, although its role in etiology differs depending
on the type of infection (uncomplicated vs. complicated)
and the patient’s characteristics. The overall percentage of
E. coli as an etiologic agent of community-acquired UTIs
in Poland decreased from 83.7 % in our previous study
published in 1998/99 to 71.4 % in 2013 [9]. However,
E. coli still predominates in uncomplicated UTIs
(80.6 %) and even more so in younger females aged less
than 30 years (88.9 %). A multicenter study (ARESC) on
uncomplicated UTIs carried out in nine European coun-
tries and Brazil showed that E. coli was responsible for
76.7 % of infections, ranging from 68.1 % in Austria to
83.8 % in France [10]. Among Polish isolates included in
this study, E. coli was responsible for 75.6 %, which is
somewhat lower than that revealed in the present
investigation.
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In this study, we observed a decreasing percentage of
E. coli among the Enterobacteriaceae responsible for compli-
cated infections. In particular, we noted an increase in
Klebsiella spp. from 2.8 % in 1998/99 to 10.8 % in the current
study, mainly in complicated infections, resulting in an in-
crease in ESBL-positive strains and, thus, multidrug-
resistant isolates. By contrast, the percentage of Proteus spp.
did not change significantly compared with the previous study
[9]. Similar distributions of etiological agents causing UTI
have been presented by other authors [10–17]. In the current
study, over 46 % of Klebsiella spp. were found to produce
ESBLs and all but one of these isolates were recovered from
complicated infections and all but one were found to belong to
CTX-M group 1, which is the most common ESBL type in
Poland [18]. A high prevalence of ESBL-producing
Enterobacteriaceae has also been demonstrated in other stud-
ies [11, 15, 19]. A recent publication also indicates that ESBL-
producing strains are more frequent in older patients [20],
which is similar to the findings presented here.
From analyses of uncomplicated infections in the ARESC
study [10], which included data from Poland, only a low
percentage (5.6 %) of K. pneumoniae isolates producing
ESBLs were identified, and this is comparable to the results
obtained in the current paper. In our study, Proteus spp. was
particularly frequent in males, accounting for more than
16.1 % of cases compared with 5.3 % in females, which was
also reported in other publications [17, 20].
In general, Gram-positive pathogens are much less fre-
quently isolated from UTIs than the Enterobacteriaceae and
were responsible for 6.6 % of all infections in this study and
5 % in our previous study [9]. Similar data are also published
from other countries [15, 21, 22]. In the present study, only
E. faecalis and S. agalactiae were recovered, with no single
isolate of S. saprophyticus. The lack of the isolation of the
latter species may result from the fact that they are mainly
responsible for uncomplicated infections in young women,
who constituted only 19 % (n=56) of our collection. This
group of patients is usually given empiric treatment without
taking a sample for culture [10, 16, 21, 23, 24]. Another rea-
son for the lack of S. saprophyticus in our study collection
could be due to the time of the year over which the study
was conducted, i.e., winter, as it was previously observed in
Table 1 Susceptibility of all Enterobacteriaceae rods and Escherichia coli isolated from uncomplicated and complicated community-acquired urinary
tract infections (UTIs) to various antimicrobial agents













Susceptible strains (n’; %)
n’ (%) n’ (%) n’ (%) n’ (%) n’ (%) n’ (%)
Ampicillin 134 (38.6 %) 118 (43.4 %) 58 (43.6 %) 55 (47.4 %) 76 (35.5 %) 63 (40.4 %)
Amoxicillin/clavulanic
acid
295 (84.0 %) 240 (88.2 %) 120 (90.2 %) 106 (91.4 %) 175 (81.8 %) 134 (85.9 %)
Piperacillin/tazobactam 310 (89.3 %) 253 (93.0 %) 131 (98.5 %) 115 (99.1 %) 179 (83.6 %) 138 (88.5 %)
Cefuroxime 285 (82.1 %) 245 (90.1 %) 120 (90.2 %) 108 (93.1 %) 165 (77.1 %) 137 (87.8 %)
Cefotaxime 300 (86.5 %) 256 (94.1 %) 128 (96.2 %) 114 (98.2 %) 172 (80.4 %) 142 (91.0 %)
Ceftazidime 306 (88.2 %) 259 (95.2 %) 127 (95.5 %) 114 (98.2 %) 179 (83.6 %) 145 (93.0 %)
Cefixime 310 (89.3 %) 260 (95.6 %) 128 (96.2 %) 114 (98.2 %) 183 (85.5 %) 146 (93.6 %)
Cefepime 316 (91.1 %) 264 (97.1 %) 129 (94.9 %) 115 (99.1 %) 187 (87.4 %) 149 (95.5 %)
Imipenem 344 (99.1 %) 272 (100 %) 131 (98.5 %) 116 (100 %) 213 (99.5 %) 156 (100 %)
Meropenem 347 (100 %) 272 (100 %) 133 (100 %) 116 (100 %) 214 (100 %) 156 (100 %)
Amikacin 333 (96.0 %) 269 (98.9 %) 132 (99.3 %) 116 (100 %) 201 (93.9 %) 153 (98.1 %)
Gentamicin 308 (88.8 %) 252 (92.7 %) 124 (93.2 %) 110 (94.8 %) 184 (86.0 %) 142 (91.0 %)
Ciprofloxacin 211 (60.8 %) 179 (65.8 %) 98 (73.7 %) 97 (75.9 %) 113 (52.8 %) 91 (58.3 %)
Nitrofurantoin 194 (55.9 %) 174 (64.0 %) 81 (60.9 %) 88 (67.2 %) 113 (52.8 %) 98 (62.8 %)
Fosfomycin nd 188 (66.4 %) nd 90 (77.6 %) nd 97 (62.2 %)
Trimethoprim/
sulfamethoxazole
209 (60.2 %) 177 (65.1 %) 89 (66.9 %) 79 (68.1 %) 120 (56.1 %) 98 (62.8 %)
nd, not determined
a Enterobacteriaceae strains responsible for UTIs: E. coli (n= 272), K. pneumoniae (n = 39), K. oxytoca (n= 2), P. mirabilis (n = 25), P. vulgaris (n = 2),
P. rettgeri (n= 1), C. freundii (n = 2), C. koseri (n= 1), E. cloacae (n= 1), S. marcescens (n = 1), M. morganii (n= 1)
b Enterobacteriaceae strains responsible for uncomplicated UTIs: E. coli (n = 116), K. pneumoniae (n= 9), P. mirabilis (n = 5), C. freundii (n= 1),
C. koseri (n= 1), M. morganii (n = 1)
c Enterobacteriaceae strains responsible for complicated UTIs: E. coli (n = 156), K. pneumoniae (n = 30), K. oxytoca (n = 2), P. mirabilis (n = 20),
P. vulgaris (n= 2), P. rettgeri (n= 1), C. freundii (n= 1), E. cloacae (n= 1), S. marcescens (n = 1)
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a previous study from Europe and the US that the prevalence
of this pathogen varies depending on the time of the year
observed [10, 21, 25]. In the ARESC study, S. saprophyticus
was found to be responsible for only 4.2 % of all cases of
uncomplicated UTI [26].
Several recent studies have underlined an important
change in resistance patterns among urinary pathogens.
Since E. coli is the leading cause of UTI, an increase in
resistance of this pathogen is of particular concern.
Although the proportion of ESBL-producers among this
pathogen and the other members of Enterobacteriaceae
has not increased compared to our earlier study, the pro-
portion of resistance to other antibiotics has increased
substantially. The most notable changes among E. coli
causing uncomplicated UTI cases have been observed
for nitrofurantoin, ciprofloxacin, trimethoprim/sulfa-
methoxazole, and fosfomycin, with susceptibility to
nitrofurantoin decreasing to 67.2 % (from 91.2 % in
the previous study), susceptibility to ciprofloxacin de-
creasing to 73.7 % (from 96.1 %), susceptibility to
trimethoprim/sulfamethoxazole decreasing to 68.1 %
(from 80.9 %), and susceptibility to fosfomycin decreas-
ing to 77.6 % (from 96.7 %) [9]. Additionally, important
differences in susceptibility were noticed between E. coli
isolated from younger (aged less than 65 years) and
older (aged 65 years and more) females in a study of
uncomplicated infections, especially in terms of suscep-
tibility to ciprofloxacin (88.8 % vs. 54.5 %) and
trimethoprim/sulfamethoxazole (76.4 % vs. 54.6 %).
Similar results have been reported in a recent paper from
Hong Kong [27]. This may be due to the fact that older
females usually have more recurrent infections that were
previously treated and could have had more contact with
hospital settings.
Two recent studies have underlined that E. coli is isolated
less frequently from males than from females and that isolates
from complicated infections in males are much more resistant
[17, 28]. Our study confirmed this finding. The percentage of
isolates susceptible to ciprofloxacin in E. coli strains from
females and males were 62 % and 46.5 %, respectively, and
to trimethoprim/sulfamethoxazole were 68.1 % and 48.8 %,
respectively. Nitrofurantoin is one of the most frequently used
drugs for treating uncomplicated UTIs, and resistance to this
drug is generally very low, as indicated by numerous studies
[29–31], including earlier data from Poland [9, 10, 22, 26]. A
high proportion of resistance to this drug among E. coli as
presented in this study is of concern. The only explanation
for this finding could be the very high consumption of
furazidin, a member of the same chemical group as
nitrofurantoin, in Poland. This drug has been available with-
out prescription in Poland since 2011. The sales have been
increasing steadily year-on-year and its consumption as mea-
sured in defined daily doses (DDD) per 1000 population per
day has increased from 2.13 in 2010 to 2.83 in 2012, an in-
crease of 32.9 %. Looking at the susceptibility data of the
isolates from complicated UTIs examined in this study, the
treatment options for oral therapy are very limited, since less
than 60 % of E. coli were susceptible to ciprofloxacin and
slightly over 63 % were susceptible to trimethoprim/
sulfamethoxazole.
The increasing resistance among bacterial populations of
urinary tract pathogens is particularly indicated by the grow-
ing number of multidrug-resistant strains. Multidrug resis-
tance is defined as non-susceptibility to at least one agent in
each of three or more antimicrobial groups [32]. Important
differences between countries and regions with regard to the
percentage of MDR among E. coli UTI isolates have been
reported, ranging from 16.7 % in Portugal to 34 % in
California, and as high as 76.5 % in India [29, 33, 34]. In
our study, multidrug-resistant E. coli isolated from complicat-
ed infections was found to be 41 %. The most common risk
factors associated with multidrug-resistant E. coli, identified
in almost 21 % of patients in our study, were nephritis and
other renal pathologies, while in a study from India, diabetes
was determined to be one of the most common risk factors for
multidrug resistant E. coli, in addition to renal pathologies
[34].
Multidrug resistance is the most rapidly increasing resis-
tance phenotype, particularly among K. pneumoniae, due to
the efficient spread of ESBL-producing, and more recently
carbapenemase-producing, strains [35–38]. Currently, such
strains are mostly isolated from hospitalized patients, but their
presence is now increasing rapidly in the community. In our
study, 71.8 % of K. pneumoniae presented with the multidrug
resistance phenotype, with the most common resistance pat-
tern including resistance to cefuroxime, ceftazidime, cipro-
floxacin, and trimethoprim/sulfamethoxazole. Ongoing mon-
itoring of resistance trends is of great importance.
Conclusion
This study presents the changing etiology of urinary tract in-
fections (UTIs) in Poland over the past 14 years and demon-
strates an increase in multidrug-resistant strains, especially
among the leading pathogens associated with UTIs, including
Escherichia coli, Klebsiella spp., and Proteus spp. It also
highlights the importance of ongoing surveillance at the local
level in order to guide empiric treatment recommendations for
local use.
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